guardant health patient lab report

How do I contact Guardant Health patient services?

You can contact Guardant Health Patient Services via phone at 855.698.8887 or via email at clientservices@guardanthealth.com. Title Guardant360® CDx | Patient Brochure

Where can I find information on Guardant Health Studies?

Information on Guardant Health studies can be found on clinicaltrials.gov. Medical professionals and clinical researchers may also email us to learn more about study participation. Imagine a day when screening for cancer is as simple as performing a blood test.

What is guardant access and how does it work?

Guardant Access is a program that manages the entire billing process at no cost to you, striving to ensure that you do not receive a surprise bill. Guardant Access

What is the guardant360 tissuenext test?

Our Guardant360 TissueNext™ test can be ordered alongside our Guardant360 CDx test. This “blood-first, tissue-next” approach offers oncologists the most efficient way to perform complete genomic testing and ensure that as many patients as possible are identified who may benefit from biomarker-informed treatment.

What is the Guardant blood test?

Guardant Health's new blood test sifts for fragments of tumor DNA floating in the bloodstream and can help detect recurring cancers months earlier than the current standard imaging procedures and blood tests for carcinoembryonic antigen levels, according to the company. ( Pixabay)

Is Guardant reveal FDA-approved?

On August 7, 2020, the U.S. Food and Drug Administration (FDA) approved the Guardant360CDx for comprehensive genomic profiling across all solid cancers and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) alterations who may benefit from ...

What is Guardant reveal?

Our Guardant Reveal™ test is the first blood-only test that detects residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease who may benefit most from adjuvant therapy.

Is Guardant health a pharmaceutical company?

Guardant Health, Inc. operates as a biotechnology company. The Company provides sequencing and cell diagnostics services for the cancer patients. Guardant Health serves patients worldwide.

Is Guardant 360 a NGS test?

The Guardant360 CDx assay uses NGS technology to simultaneously detect mutations in 55 tumor genes, rather than one gene at a time.

Is Guardant 360 Next Generation Sequencing?

Guardant360 CDx is a next generation sequencing-based test for the detection of genetic alterations in 55 genes frequently mutated in cancer.

What is liquid biopsy test?

Listen to pronunciation. (LIH-kwid BY-op-see) A test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. A liquid biopsy may be used to help find cancer at an early stage.

What is ctDNA testing?

As cancer cells go through their life cycle, fragments of DNA can enter the bloodstream. This is known as circulating tumor DNA – or ctDNA, for short. ctDNA testing examines a patient's blood to detect DNA fragments from cancer cells.

What is Signatera?

Signatera is a MRD blood test that is personalized to each patient's set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.

Who owns Guardant health?

The Vanguard Group, Inc.

Who are Guardant Health competitors?

Guardant Health's top competitors include Sophia Genetics, Caris Life Sciences, Castle Biosciences, Biodesix and Tempus. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy.

What kind of company is Guardant health?

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.

Who founded Guardant?

Guardant Health raises a $10,000,000 series A round from Sequoia Capital. Guardant Health was founded by AmirAli Talasaz, HELMY ELTOUKHY, PHD and HELMY ELTOUKHY, PHD.

Where is Guardant Health located?

Redwood City, CACompany Description: Guardant Health, Inc. is located in Redwood City, CA, United States and is part of the Medical and Diagnostic Laboratories Industry.

When did Guardant health go public?

Oct 4, 2018IPO & Stock Price Guardant Health is registered under the ticker NASDAQ:GH . Their stock opened with $19.00 in its Oct 4, 2018 IPO.

How large is Guardant health?

Guardant Health continues to expect full year 2022 revenue to be in the range of $460 million to $470 million, representing 23% to 26% growth over full year 2021.

The first FDA-approved blood test for complete genomic testing

Our Guardant360 ® CDx test is FDA-approved for complete genomic testing across all solid cancers, providing doctors guideline-complete genomic results in 7 days from a simple blood draw to inform treatment decisions.

Results from a tissue biopsy available when needed

Our Guardant360 TissueNext™ test can be ordered alongside our Guardant360 CDx test. This “blood-first, tissue-next” approach offers oncologists the most efficient way to perform complete genomic testing and ensure that as many patients as possible are identified who may benefit from biomarker-informed treatment.

An earlier view of patient response to treatment

Our Guardant360 Response ™ test is the first blood-only test that enables doctors to view molecular response, or changes in circulating tumor DNA (ctDNA) levels, from a simple blood draw to get an early indication of patient response to immunotherapy or targeted therapy.

ECLIPSE

Evaluation of ctDNA Guardant LUNAR2 Assay In an Average Patient Screening Episode (ECLIPSE) will evaluate whether early signs of colorectal cancer can be detected by a simple blood test.

GRECO-Breast Cancer

Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer (GRECO-Breast Cancer) will evaluate the role the Guardant360 plays in determining patient’s treatment plan and how well that treatment plan controlled their cancer.

About Us

Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.

Solutions

The Guardant360 ® assay is a breakthrough liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw in approximately seven days upon receipt in the US laboratory.

News & Events

The quick turnaround time of the Guardant360® liquid biopsy test allows for shorter time to treatment for patients with advanced stage cancer compared…